Oragenics Regains NYSE Compliance and Advances Neurological Therapeutics Platform with AI Partnership

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics via proprietary intranasal delivery technology, has regained full NYSE American compliance while reporting substantial third quarter 2025 progress. The company has established clinical infrastructure in Australia and is preparing for its first-ever Phase IIa trial of ONP-002, its lead candidate for concussion treatment. This regulatory milestone and clinical advancement signal the company's strengthened position in the competitive neurological therapeutics space.

The company simultaneously announced a strategic collaboration with Receptor.AI to expand its neurological therapeutics pipeline using artificial intelligence to identify and validate next-generation candidates. This partnership aims to accelerate development for conditions such as Parkinson's, Alzheimer's, PTSD, and anxiety disorders. The AI-driven approach represents a significant shift in how neurological drug discovery is conducted, potentially reducing development timelines and improving candidate selection accuracy. Additional details about this collaboration can be found at https://ibn.fm/rLGMC.

CEO Janet Huffman emphasized the company's broader vision, stating "We're not building a one-drug company—we're building a neurological therapeutics platform." This platform approach leverages the company's proprietary intranasal delivery technology, which has the potential to enable targeted, non-invasive therapeutics for brain-related conditions. The technology platform could open pathways to address neurodegenerative diseases, CNS disorders, and other neurological conditions beyond the initial focus on concussion treatment.

The company's progress comes at a critical time when neurological disorders represent a growing global health challenge. With an aging population and increasing awareness of brain health, the market for effective neurological treatments continues to expand. Oragenics' dual approach of advancing its lead candidate while building a broader pipeline through AI collaboration positions the company to potentially address multiple neurological conditions with its platform technology. Investors can monitor the company's ongoing developments through its newsroom at https://ibn.fm/OGEN.

The combination of regulatory compliance, clinical trial progress, and strategic AI partnership demonstrates Oragenics' commitment to transforming neurological care. The company's focus on brain-first recovery represents a comprehensive approach to neurological trauma that could potentially benefit patients, clinicians, and healthcare systems. As the company moves forward with its Phase IIa trial and AI-driven pipeline expansion, it aims to establish itself as a significant player in the neurological therapeutics landscape.